Across the recent three months, 12 analysts have shared their insights on Doximity DOCS, expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 2 | 9 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 1 | 0 | 0 |
| 2M Ago | 0 | 0 | 2 | 0 | 0 |
| 3M Ago | 0 | 1 | 6 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Doximity, presenting an average target of $58.33, a high estimate of $82.00, and a low estimate of $43.00. Surpassing the previous average price target of $46.67, the current average has increased by 24.98%.
Investigating Analyst Ratings: An Elaborate Study
The perception of Doximity by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Scott Berg | Needham | Raises | Buy | $82.00 | $65.00 |
| Stan Berenshteyn | Wells Fargo | Raises | Equal-Weight | $43.00 | $41.00 |
| Scott Schoenhaus | Keybanc | Lowers | Overweight | $65.00 | $70.00 |
| Allen Lutz | B of A Securities | Raises | Neutral | $57.00 | $54.00 |
| Jeff Garro | Stephens & Co. | Announces | Equal-Weight | $55.00 | - |
| Steven Valiquette | Mizuho | Announces | Neutral | $55.00 | - |
| Anne Samuel | JP Morgan | Raises | Neutral | $48.00 | $30.00 |
| David Roman | Goldman Sachs | Announces | Neutral | $58.00 | - |
| Jailendra Singh | Truist Securities | Raises | Hold | $49.00 | $35.00 |
| Ricky Goldwasser | Morgan Stanley | Raises | Equal-Weight | $53.00 | $33.00 |
| Richard Close | Canaccord Genuity | Raises | Hold | $60.00 | $40.00 |
| Stephanie Davis | Barclays | Raises | Overweight | $75.00 | $52.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Doximity. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Doximity compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Doximity's stock. This comparison reveals trends in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Doximity's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Doximity analyst ratings.
Discovering Doximity: A Closer Look
Doximity Inc is a digital platform for U.S. medical professionals. Its cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers.
Key Indicators: Doximity's Financial Health
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Doximity showcased positive performance, achieving a revenue growth rate of 20.44% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Doximity's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 32.27% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Doximity's ROE excels beyond industry benchmarks, reaching 4.71%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 4.03%, the company showcases effective utilization of assets.
Debt Management: Doximity's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
The Significance of Analyst Ratings Explained
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
